Abstract HER2 (Human Epidermal Growth Factor Receptor 2), also known as ERBB2, CD340, and Neu protooncogene, is a member of the epidermal growth factor receptor (EGRF) family. Members of the ERBB family, including HER2, activate molecular cascades that stimulate proliferation and migration of cancer cells, as well as their resistance to the anticancer therapy. These proteins are often overexpressed and/or mutated in various cancer types and represent promising targets for the anti-cancer therapy. Currently, anti-HER2 drugs have been approved for the treatment of several types of solid tumors. HER2-specific therapy includes monoclonal antibodies and low-molecular weight inhibitors of tyrosine kinase receptors, such as lapatinib, neratinib, and pyrotinib. In addition to the activation of molecular pathways responsible for cell proliferation and survival under stress conditions, HER2 directly regulates programmed cell death. Here, we review the studies focused on the involvement of HER2 in various signaling pathways and its role in the regulation of apoptosis.

中文翻译：

---

ERBB2/HER2酪氨酸激酶受体在细胞死亡调控中的作用

摘要 HER2（Human Epidermal Growth Factor Receptor 2）又称ERBB2、CD340、Neu原癌基因，是表皮生长因子受体（EGRF）家族的一员。ERBB 家族的成员，包括 HER2，激活刺激癌细胞增殖和迁移的分子级联反应，以及它们对抗癌疗法的抵抗力。这些蛋白质通常在各种癌症类型中过度表达和/或突变，代表了抗癌治疗的有希望的靶点。目前，抗HER2药物已被批准用于治疗多种类型的实体瘤。HER2 特异性治疗包括单克隆抗体和酪氨酸激酶受体的低分子量抑制剂，如拉帕替尼、来那替尼和吡罗替尼。除了在应激条件下激活负责细胞增殖和存活的分子途径外，HER2 还直接调节程序性细胞死亡。在这里，我们回顾了侧重于 HER2 参与各种信号通路及其在调节细胞凋亡中的作用的研究。